Psychedelics are a mental health miracle — so why is the FDA holding back? 

The U.S. Food and Drug Administration just rejected an application that would have authorized the use of a promising psychedelic compound, MDMA, for the treatment of post-traumatic stress disorder, a condition affecting 13 million Americans, In its denial, the FDA suggested the company, Lykos Therapeutics, instead conduct another large study — a proposal that could take years.